- Home
- BNL vs KNSA Comparison
BNL vs KNSA Comparison
Compare BNL & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNL | KNSA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BNL | KNSA |
|---|---|---|
| Price | $18.67 | $46.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $20.22 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 1.6M | 672.2K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.28% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | 0.50 | ★ 0.75 |
| Revenue | $454,138,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $7.54 | $38.01 |
| Revenue Next Year | $6.64 | $17.42 |
| P/E Ratio | ★ $37.27 | $61.35 |
| Revenue Growth | 5.17 | ★ 60.09 |
| 52 Week Low | $13.96 | $18.26 |
| 52 Week High | $19.91 | $49.12 |
Technical Indicators
Market Signals| Indicator | BNL | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 52.43 |
| Support Level | $18.56 | $39.96 |
| Resistance Level | $18.77 | $48.14 |
| Average True Range (ATR) | 0.40 | 1.79 |
| MACD | -0.08 | -0.15 |
| Stochastic Oscillator | 15.60 | 58.86 |
Price Performance
Historical ComparisonAbout BNL Broadstone Net Lease Inc.
Broadstone Net Lease Inc is an internally managed real estate investment trust that invests in, owns, and manages single-tenant commercial real estate properties that are net leased on a long-term basis to a diversified group of tenants. The company has selectively invested in net leased assets in the industrial, healthcare, restaurant, retail, and office property types. The company focuses on investing in real estate that is operated by creditworthy single tenants in industries characterized by positive business drivers and trends. The company targets properties that are an integral part of the tenants' businesses and are therefore opportunities to secure long-term net leases.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.